ArticleJournal of Indian Society of Periodontology
Galectin-3 as a biomarker for periodontal disease severity in postcoronavirus disease 2019 patients: A clinical and biochemical investigation.
Article in Journal of Indian Society of Periodontology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The relationship between coronavirus disease 2019 (COVID-19) and periodontitis has been interesting. Understanding this connection is crucial for comprehensive patient care and highlights the importance of monitoring and addressing oral health issues in an individual's post-COVID-19 recovery. This study compared and evaluated the serum Galectin-3 (Gal-3) levels and clinical parameters in healthy individuals with chronic periodontitis with no history of COVID-19 and post-COVID-19 patients with periodontitis. Materials and Methods: Group I consists of 25 post-COVID-19 patients with Stage II Grade B periodontitis, 25 patients with Stage II Grade B periodontitis without any history of COVID-19 (Group II), and 25 healthy controls (Group III) were recruited for the study. Gal-3 levels in serum were assessed using an enzyme-linked immunosorbent assay (ELISA) kit. Clinical periodontal variables were measured and recorded, including clinical attachment level (CAL), plaque index (PI), and probing pocket depth (PPD). Data analyses were done using the one-way analysis of variance (ANOVA) test and Tukey's honest significant difference Results: Group I patients had a higher serum Gal-3 concentrations of 14.757 ng/ml compared to 11.127 ng/ml and 8.673 ng/ml in Group II and Group III, respectively, and the mean difference in Gal-3 levels was statistically significant with Conclusion: The current study's findings demonstrated that periodontitis patients and individuals with post-COVID-19 and periodontitis had increased Gal-3 levels in the serum compared to healthy participants. This study highlights the relevance of treating periodontitis during the post-COVID-19/long-COVID era and the need to maintain oral hygiene by identifying possible biomarkers and understanding specific underlying processes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.